ArticlePLOS global public health2026
Assessing the impact of a gender-neutral approach to HPV vaccination on vaccination coverage for nine-year-old girls in Cameroon: A retrospective, cross-sectional study.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cameroon introduced the human papilloma virus vaccine (HPVV) into the routine immunization schedule in October 2020. By the end of 2022, coverage remained low. To increase coverage, Cameroon switched to a country-wide, gender-neutral vaccination (GNV) approach in 2023, coupled with a revamped delivery strategy of Community Dialogues (CDs) and Periodic Intensification of Routine Immunization (PIRIs) activities in selected health districts (HDs). We assessed the impact of these programmatic changes, notably the GNV approach, on HPVV coverage. This retrospective, cross-sectional study measured the effect of GNV and CDs+PIRIs on HPVV coverage among 9-year-old girls in Cameroon (2022-2023). Data on HPV vaccination from all 203 HDs were extracted from DHIS2, and coveragecalculated at the HD level based on the estimated population eligible of 9-year-old girls. Descriptive statistics and multiple regression models were employed to assess the impact of GNV on vaccination coverage, while adjusting for CDs+PIRIs, baseline (2022) coverage, region, urban/rural status. In 2023, of the 203 HDs, 115 (56.7%) conducted GNV only and 74 (36.5%) implemented GNV & CDs+PIRIs. Among age-eligible girls, there was an overall increase in HPV vaccination coverage, with coverage rising 39.2 percentage points from 2022 to 2023. Following multiple linear regression, there was a significant association between percentage point increase in HPVV coverage in HDs with GNV & CDs+PIRIs, compared to those with no GNV and no CDs+PIRIs in the adjusted model (β:44.5, 95%CI: 29.4, 59.6, p < 0.001). Furthermore, there was a significant association between increase in HPVV coverage in HDs with GNV only compared to those with no GNV or no CDs+PIRIs in the adjusted model (β:15.5, 95%CI: 1.23, 29.8 p < 0.001). Overall, the GNV approach was associated with an increase in HPVV coverage for girls, with greater magnitude and predicted precision when implemented alongside CDs+PIRIs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.